Relationship between low-normal blood pressure and kidney disease in type 1 diabetes

Hypertension

Volumn 49, Issue 1, 2007, Pages 48-54

  Shankar, Anoop ^a   Klein, Ronald ^b   Klein, Barbara E K ^b   Nieto, F Javier ^b   Moss, Scot E ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Blood pressure; Chronic kidney disease; GFR; Proteinuria; Type 1 diabetes; WESDR

Indexed keywords

ADULT; ARTICLE; BLOOD PRESSURE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPOTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; UNITED STATES; DIABETIC NEPHROPATHY; DIASTOLE; PATHOPHYSIOLOGY; RISK; SYSTOLE;

ADULT; BLOOD PRESSURE; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIASTOLE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; MALE; PROTEINURIA; RISK; SYSTOLE;

EID: 33847643616     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000252431.75154.3a     Document Type: Article

References (50)

1. US Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health, 2005.
2. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension. 1995;26:869-879.
3. Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001;161:2661-2667.
4. American Diabetes Association. Treatment of hypertension in adults with diabetes (position statement). Diabetes Care. 2002;25(suppl 1):S71-S73.
5. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(suppl 2):B54-B64.
6. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412-419.
7. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
8. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care. 2002;25:134-147.
9. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086-1097.
10. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128:982-988.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
12. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342:381-389.
13. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
14. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
15. Cefalu WT. Glycemic control and cardiovascular disease-should we reassess clinical goals. N Engl J Med. 2005;353:2707-2709.
16. Orchard TJ, Forrest KY, Kuller LH, Becker DJ. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2001;24:1053-1059.
17. Klein R, Klein BE, Moss SE, DeMets DL, Kaufman I, Voss PS. Prevalence of diabetes mellitus in southern Wisconsin. Am J Epidemiol. 1984;119:54-61.
18. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four- year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1989;107:237-243.
19. Klein R, Klein BE, Moss SE, Cruickshanks KJ, Brazy PC. The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care. 1999;22:743-751.
20. Klein R, Klein BE, Moss S, DeMets DL. Proteinuria in diabetes. Arch Intern Med. 1988;148:181-186.
21. Klein R, Klein BE, Moss SE, Cruickshanks KJ. Ten-year incidence of gross proteinuria in people with diabetes. Diabetes. 1995;44:916-923.
22. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. Wisconsin Epidemiologic Study of Diabetic Retinopathy. XII. Relationship of C-peptide and diabetic retinopathy. Diabetes. 1990;39:1445-1450.
23. Diabetic Retinopathy Study Research Group. Report Number 7: a modification of the Airlie House classification of diabetic retinopathy. Invest Ophthalmol Vis Sci. 1981;21:210-226.
24. Moss SE, Klein R, Klein BE, Spennetta TL, Shrago ES. Methodologic considerations in measuring glycosylated hemoglobin in epidemiologic studies. J Clin Epidemiol. 1988;41:645-649.
25. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
26. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ. 1992;304:339-343.
27. Szklo M, Nieto FJ. Epidemiology beyond the basics. Gaithersburg, MD: Aspen; 2000.
28. Kincaid-Smith P, McMichael J, Murphy EA. The clinical course and pathology of hypertension with papilloedema (malignant hypertension). Q J Med. 1958;27:117-153.
29. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18.
30. Perneger TV, Nieto FJ, Whelton PK, Klag MJ, Comstock GW, Szklo M. A prospective study of blood pressure and serum creatinine. Results from the 'Clue' Study and the ARIC Study. JAMA. 1993;269:488-493.
31. Pettinger WA, Lee HC, Reisch J, Mitchell HC. Long-term improvement in renal function after short-term strict blood pressure control in hypertensive nephrosclerosis. Hypertension. 1989;13:766-772.
32. Young JH, Klag MJ, Muntner P, Whyte JL, Pahor M, Coresh J. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol. 2002;13:2776-2782.
33. Wiederkehr M, Toto R, Fenves AZ, Ram CV. Hypertension and the kidney. Semin Nephrol. 2005;25:236-245.
34. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983;1:1175-1179.
35. Christensen CK, Mogensen CE. Antihypertensive treatment: long-term reversal of progression of albuminuria in incipient diabetic nephropathy. A longitudinal study of renal function. J Diabet Complications. 1987;1:45-52.
36. Jamerson KA. Preventing chronic kidney disease in special populations. Am J Hypertens. 2005;18:106S-111S.
37. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis. 1999;34:809-817.
38. Wilmer WA, Hebert LA, Lewis EJ, Rohde RD, Whittier F, Cattran D, Levey AS, Lewis JB, Spitalewitz S, Blumenthal S, Bain RP. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis. 1999;34:308-314.
39. Tilton RG, Pugliese G, Faller AM, LaRose LS, Province MA, Williamson JR. Interactions between hypertension and diabetes on vascular function and structure in rats. J Diabetes Complications. 1992;6:187-196.
40. Tsao PS, Niebauer J, Buitrago R, Lin PS, Wang BY, Cooke JP, Chen YD, Reaven GM. Interaction of diabetes and hypertension on determinants of endothelial adhesiveness. Arterioscler Thromb Vasc Biol. 1998;18:947-953.
41. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994;271:275-279.
42. Cook J, Daneman D, Spino M, Sochett E, Perlman K, Balfe JW. Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus. J Pediatr. 1990;117:39-45.
43. Vilarrasa N, Soler J, Montanya E. Regression of microalbuminuria in type 1 diabetic patients: results of a sequential intervention with improved metabolic control and ACE inhibitors. Acta Diabetol. 2005;42:87-94.
44. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
45. Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ. 1988;297:1092-1095.
46. Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ. 1991;303:81-87.
47. Hansen KW, Mau PM, Christensen CK, Schmitz A, Christiansen JS, Mogensen CE. Normoalbuminuria ensures no reduction of renal function in type 1 (insulin-dependent) diabetic patients. J Intern Med. 1992;232:161-167.
48. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1:581-584.
49. Alderman MH, Ooi WL, Madhavan S, Cohen H. Treatment-induced blood pressure reduction and the risk of myocardial infarction. JAMA. 1989;262:920-924.
50. Panes J, Kurose I, Rodriguez-Vaca D, Anderson DC, Miyasaka M, Tso P, Granger DN. Diabetes exacerbates inflammatory responses to ischemia-reperfusion. Circulation. 1996;93:161-167.